Glucagon-like receptor 1 agonists and DPP-4 inhibitors: potential therapies for the treatment of stroke.
作者： Vladimer Darsalia , Martin Larsson , David Nathanson , Thomas Klein , Thomas Nyström
关键词:
摘要: During the past decades, candidate drugs that have shown neuroprotective efficacy in preclinical setting failed clinical stroke trials. As a result, no treatment for based on neuroprotection is available today. The activation of glucagon-like peptide 1 receptor (GLP-1) reducing damage relatively novel concept has effects animal models. In addition, studies are currently ongoing. Herein, we review this emerging research field and discuss next milestones to be achieved develop antistroke therapy.
sagepub.com
nature.com
sci-hub.se 参考文章(30)
Dimitra Magkou, Konstantinos Tziomalos, Antidiabetic treatment, stroke severity and outcome World Journal of Diabetes. ,vol. 5, pp. 84- 88 ,(2014) , 10.4239/WJD.V5.I2.84
Samantha C. Daly, Thomas Chemmanam, Poh-Sien Loh, Amanda Gilligan, Anthony E. Dear, Richard W. Simpson, Christopher F. Bladin, Exenatide in acute ischemic stroke International Journal of Stroke. ,vol. 8, ,(2013) , 10.1111/IJS.12073
Göran Bertilsson, Cesare Patrone, Olof Zachrisson, Annica Andersson, Karin Dannaeus, Jessica Heidrich, Jarkko Kortesmaa, Alex Mercer, Elisabet Nielsen, Harriet Rönnholm, Lilian Wikström, Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of parkinson's disease Journal of Neuroscience Research. ,vol. 86, pp. 326- 338 ,(2008) , 10.1002/JNR.21483
Vladimer Darsalia, Sansan Hua, Martin Larsson, Carina Mallard, David Nathanson, Thomas Nyström, Åke Sjöholm, Maria E. Johansson, Cesare Patrone, Exendin-4 reduces ischemic brain injury in normal and aged type 2 diabetic mice and promotes microglial M2 polarization. PLOS ONE. ,vol. 9, ,(2014) , 10.1371/JOURNAL.PONE.0103114
Yu Dennis Cheng, Lama Al-Khoury, Justin A. Zivin, Neuroprotection for ischemic stroke: Two decades of success and failure Neurorx. ,vol. 1, pp. 36- 45 ,(2004) , 10.1602/NEURORX.1.1.36
Dirk Sander, Mark T. Kearney, Reducing the risk of stroke in type 2 diabetes: pathophysiological and therapeutic perspectives. Journal of Neurology. ,vol. 256, pp. 1603- 1619 ,(2009) , 10.1007/S00415-009-5143-1
Matteo Monami, Ilaria Dicembrini, Daniele Martelli, Edoardo Mannucci, Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Current Medical Research and Opinion. ,vol. 27, pp. 57- 64 ,(2011) , 10.1185/03007995.2011.602964
Choong Hyun Lee, Bingchun Yan, Ki-Yeon Yoo, Jung Hoon Choi, Seung-Hae Kwon, Song Her, Youdong Sohn, In Koo Hwang, Jun Hwi Cho, Young-Myeong Kim, Moo-Ho Won, Ischemia-induced changes in glucagon-like peptide-1 receptor and neuroprotective effect of its agonist, exendin-4, in experimental transient cerebral ischemia. Journal of Neuroscience Research. ,vol. 89, pp. 1103- 1113 ,(2011) , 10.1002/JNR.22596
Vladimer Darsalia, Shiva Mansouri, Henrik Ortsäter, Anna Olverling, Nino Nozadze, Camilla Kappe, Kerstin Iverfeldt, Linda M. Tracy, Nina Grankvist, Åke Sjöholm, Cesare Patrone, Glucagon-like peptide-1 receptor activation reduces ischaemic brain damage following stroke in Type 2 diabetic rats Clinical Science. ,vol. 122, pp. 473- 483 ,(2012) , 10.1042/CS20110374
Alison Hamilton, Christian Hölscher, Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system. Neuroreport. ,vol. 20, pp. 1161- 1166 ,(2009) , 10.1097/WNR.0B013E32832FBF14